A two-cohort study reported that a blood-based DNA methylation panel targeting HYAL2, S100P and DYRK4—combined with routine blood count parameters—can detect esophageal squamous cell carcinoma with high accuracy. The approach aims to provide a less invasive screening or early detection pathway where endoscopy is costly or delayed. The key translational step is validation across additional populations and assay-to-assay reproducibility, especially for methylation panels where pre-analytical variables can affect performance. If confirmed, the model could support earlier stratification of patients for diagnostic workups and treatment planning.